Advanced neuroendocrine prostate tumors regress to stemness
نویسندگان
چکیده
منابع مشابه
Advanced neuroendocrine prostate tumors regress to stemness.
Leigh Ellis and Massimo Loda Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263; Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana–Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, MA 02115...
متن کاملSystemic therapies for advanced gastroenteropancreatic neuroendocrine tumors
Introduction: Neuroendocrine tumors are a heterogeneous group of malignancies, characterised by production of hormones and vasoactive peptides. The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) is rising, and they have the highest prevalence amongst upper gastro-intestinal tumors. Diagnosis remains challenging due to wide variations in presentation and slow onset of sympto...
متن کاملSystemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Pancreatic neuroendocrine tumors are an uncommon tumor type and compose 1% to 2% of all pancreatic neoplasms. They are rarely localized at presentation and are typically diagnosed in the presence of metastatic disease. The management poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. A variety of systemic therapies have been ...
متن کاملEmerging treatment modalities for advanced pancreatic neuroendocrine tumors.
It was with great interest that we read the article titled “Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?” by I. Perysinakis et al published in the first issue of 2016 of the Journal.1 The authors review the recent literature concerning advanced pancreatic neuroendocrine tumors (pNETs) and highlight the fact that there is increasing evidence ...
متن کاملTreatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
Pancreatic neuroendocrine tumors (PanNETs) are frequently diagnosed at unresectable stage and remain a medical challenge. Everolimus (RAD001, Afinitor(®), Novartis, Basel, Switzerland), an orally administered inhibitor of mammalian target of rapamycin (mTOR), was recently approved by the Food and Drug Administration to treat patients with advanced PanNETs. This review will examine the mechanism...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the National Academy of Sciences
سال: 2015
ISSN: 0027-8424,1091-6490
DOI: 10.1073/pnas.1519151112